首页> 外文期刊>中国癌症研究(英文版) >Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
【24h】

Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China

机译:基于淋巴结或淋巴结外原发灶的弥漫性大B细胞淋巴瘤的临床特征和预后:在中国一家机构中对1,085例WHO分类病例进行分析

获取原文
获取原文并翻译 | 示例
       

摘要

Objective:To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site.Methods:A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled.Their clinical characteristics and outcomes were analyzed according to the primary site.Results:In the 1,085 patients,679 (62.6%) cases were nodal DLBCL (N-DLBCL) and 406 cases (37.4%) were extranodal DLBCL (EN-DLBCL).The most common sites of N-DLBCL were lymphonodus (64.8%),Waldeyer's ring (19.7%),mediastinum (12.8%) and spleen (2.7%),while in EN-DLBCL,stomach (22.4%),intestine (16.0%),nose and sinuses (8.9%),testis (8.4%),skin (7.9%),thyroid (6.9%),central nervous system (CNS) (6.4%),breast (5.7%),bone (3.4%),and salivary gland (2.7%) were most common.N-DLBCL patients tend to present B symptoms,bulky disease,and elevated LDH more often,while age >60 years,extranodal sites >1,Ann Arbor stage Ⅰ or Ⅱ,bone marrow involvement,and Ki-67 index >90% were usually seen in EN-DLBCL.The 5-year overall survival (OS) rate and progression-free survival (PFS) rate for all patents were 62.5% and 54.2%.The 5-year OS rate for patents with N-DLBCL and EN-DLBCL were 65.5% and 56.9% (P=0.008),and the 5-year PFS were 57.0% and 49.0% (P=0.020).Waldeyer's ring originated DLBCL possessed the highest 5-year OS rate (83.6%) and PFS rate (76.9%) in N-DLBCL.The top five EN-DLBCL subtypes with favorable prognosis were stomach,breast,nose and sinuses,lung,salivary gland,with 5-year OS rate:70.3%,69.6%,69.4%,66.7% and 63.6%,respectively.While CNS,testis,oral cavity and kidney originated EN-DLBCL faced miserable prognosis,with 5-year OS rate of 26.9%,38.2%,and 42.9%.Conclusions:In our study,primary sites were associated with clinical characteristics and outcomes.Compared with EN-DLBCL,N-DLBCL had better prognosis.
机译:目的:根据原发部位,探讨中国弥漫性大B细胞淋巴瘤(DLBCL)患者的临床生物学特征和转归。方法:中国医学科学院国家癌症中心/癌症医院共诊断出1085例DLBCL患者结果:在1,085例患者中,淋巴结性DLBCL(N-DLBCL)占679例,占总病例数的62.6%。结外DLBCL(EN-DLBCL)406例(37.4%)。N-DLBCL最常见的部位是淋巴结肿大(64.8%),Waldeyer环(19.7%),纵隔(12.8%)和脾脏(2.7%),同时EN-DLBCL中的胃,胃(22.4%),肠(16.0%),鼻子和鼻窦(8.9%),睾丸(8.4%),皮肤(7.9%),甲状腺(6.9%),中枢神经系统(CNS)( N-DLBCL患者更倾向于出现B症状,大块疾病和LDH升高,最常见的是6.4%),乳腺癌(5.7%),骨骼(3.4%)和唾液腺(2.7%)。在EN-DLBCL中通常见到年龄大于60岁,胎盘部位大于1,Ann ArborⅠ或Ⅱ期,骨髓受累以及Ki-67指数> 90%。5年总生存率和所有专利的无进展生存率(PFS)分别为62.5%和54.2%。具有N-DLBCL和EN-DLBCL的专利的5年OS率分别为65.5%和56.9%(P = 0.008),以及5种N-DLBCL的5年OS率(83.6%)和PFS率(76.9%)在N-DLBCL中最高,前5种EN-DLBCL亚型分别为57.0%和49.0%(P = 0.020)。胃,乳腺,鼻窦和鼻,肺,唾液腺的预后良好,其5年OS率分别为70.3%,69.6%,69.4%,66.7%和63.6%。CNS,睾丸,口腔和肾脏起源EN-DLBCL的预后很差,五年OS率分别为26.9%,38.2%和42.9%。预后较好。

著录项

  • 来源
    《中国癌症研究(英文版)》 |2019年第1期|152-161|共10页
  • 作者单位

    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Departement of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Departement of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Departement of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Departement of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

    Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 04:25:46
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号